IRIS
BALDARI, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 29.407
NA - Nord America 20.399
AS - Asia 12.414
SA - Sud America 4.072
AF - Africa 393
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 31
Totale 66.750
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.959
RU - Federazione Russa 13.060
IT - Italia 5.390
SG - Singapore 5.138
BR - Brasile 3.505
CN - Cina 3.434
IE - Irlanda 3.083
SE - Svezia 2.936
HK - Hong Kong 1.280
DE - Germania 1.219
FR - Francia 818
VN - Vietnam 816
FI - Finlandia 635
GB - Regno Unito 598
IN - India 562
UA - Ucraina 524
NL - Olanda 379
PL - Polonia 221
CA - Canada 208
AR - Argentina 186
BD - Bangladesh 180
TR - Turchia 139
IQ - Iraq 133
MX - Messico 128
ZA - Sudafrica 119
BE - Belgio 109
JP - Giappone 92
AT - Austria 82
CO - Colombia 78
ES - Italia 75
CZ - Repubblica Ceca 73
EC - Ecuador 73
ID - Indonesia 73
PK - Pakistan 71
UZ - Uzbekistan 64
MA - Marocco 58
VE - Venezuela 57
CL - Cile 56
TN - Tunisia 49
CI - Costa d'Avorio 44
IR - Iran 41
LT - Lituania 40
SA - Arabia Saudita 40
AE - Emirati Arabi Uniti 39
PY - Paraguay 37
AZ - Azerbaigian 36
KE - Kenya 34
PH - Filippine 33
PE - Perù 31
CH - Svizzera 28
AU - Australia 27
EG - Egitto 27
UY - Uruguay 26
DZ - Algeria 23
MY - Malesia 23
IL - Israele 22
JO - Giordania 21
KG - Kirghizistan 21
PA - Panama 20
AL - Albania 19
EU - Europa 19
KZ - Kazakistan 19
NP - Nepal 19
JM - Giamaica 18
BO - Bolivia 17
PS - Palestinian Territory 16
RO - Romania 16
CR - Costa Rica 15
LB - Libano 15
GE - Georgia 14
OM - Oman 13
DO - Repubblica Dominicana 11
NO - Norvegia 11
BG - Bulgaria 10
GT - Guatemala 10
HN - Honduras 10
BY - Bielorussia 9
NI - Nicaragua 9
SN - Senegal 9
AM - Armenia 8
BH - Bahrain 8
GR - Grecia 8
PT - Portogallo 8
HU - Ungheria 7
LK - Sri Lanka 7
LV - Lettonia 7
TH - Thailandia 7
RS - Serbia 6
XK - ???statistics.table.value.countryCode.XK??? 6
DK - Danimarca 5
EE - Estonia 5
KW - Kuwait 5
MN - Mongolia 5
NG - Nigeria 5
NZ - Nuova Zelanda 5
SK - Slovacchia (Repubblica Slovacca) 5
ET - Etiopia 4
HR - Croazia 4
LU - Lussemburgo 4
LY - Libia 4
Totale 66.675
Salva come PNG Salva come JPEG
Città #
Moscow 3.864
Dublin 3.079
Ashburn 2.954
Singapore 2.641
Chandler 2.474
Dallas 2.473
Nyköping 1.665
Hong Kong 1.275
Beijing 1.260
Jacksonville 1.176
San Jose 1.142
The Dalles 611
Los Angeles 512
Princeton 506
Medford 472
Munich 459
Milan 454
Lauterbourg 427
Rome 416
Dearborn 406
Cambridge 365
Des Moines 358
New York 353
Ann Arbor 337
Messina 327
São Paulo 280
Dong Ket 236
Boardman 228
Hyderabad 215
Buffalo 207
Ho Chi Minh City 191
Warsaw 183
Naples 180
Bremen 164
Jinan 151
Tianjin 148
Lancaster 145
Wilmington 139
Turku 136
Redondo Beach 129
Helsinki 124
Hanoi 123
Shenyang 123
Pune 121
Council Bluffs 116
Orem 110
Santa Clara 108
Brussels 103
Palermo 103
Catania 101
Frankfurt am Main 101
Woodbridge 100
Guangzhou 96
Turin 96
San Mateo 92
Houston 87
Rio de Janeiro 87
Belo Horizonte 83
Bologna 82
Bari 81
Montreal 80
Nanjing 76
Brasília 75
Tokyo 75
Johannesburg 71
Chennai 70
Brooklyn 66
Florence 66
Seattle 66
Curitiba 63
London 63
Zhengzhou 62
Porto Alegre 61
Denver 59
Vienna 59
Genoa 58
Baghdad 57
Stockholm 57
Tashkent 57
Nuremberg 54
Chicago 53
Hebei 52
Atlanta 51
Ningbo 50
Nanchang 49
Campinas 48
Amsterdam 47
Hangzhou 47
Shanghai 46
Abidjan 44
Brno 43
Haikou 41
Manchester 40
Shenzhen 39
Düsseldorf 38
Mumbai 38
Poplar 38
Taizhou 38
Boston 37
Toronto 37
Totale 36.946
Salva come PNG Salva come JPEG
Nome #
LA LOCALIZZAZIONE ISTMICA DEL NODULO TIROIDEO MALIGNO RAPPRESENTA UN FATTORE ADDIZIONALE DI RISCHIO PER METASTASI IN PAZIENTI AFFETTI DA CARCINOMA DIFFERENZIATO DELLA TIROIDE (CDT) A BASSO RISCHIO 4.650
EMIAGENESIA TIROIDEA, MORBO DI BASEDOW-GRAVES E CARCINOMA DIFFERENZIATO DELLA TIROIDE: UN’ASSOCIAZIONE MOLTO RARA. 326
99mTc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology 276
Value of 99mTc-DPD scintigraphy as early diagnostic modality in familial amyloidotic polyneuropathy. 274
Aggressive pituitary adenomas: the dark side of the moon 268
131I RADIOIODINE THERAPY (RIT) OF HYPERTYROIDISM DUE TO GRAVES’ DISEASE (GD) OR UNI-MULTINODULAR TOXIC GOITER (NTG): OUR EXPERIENCE 257
131I Radioiodine therapy (RIT) of hyperthyroidism due to Graves' disease (GD) or uni-multinodular toxic goiter (NTG): our experience 247
111In-Pentetreotide for treatment of neuroendocrine tumours: an alternative therapeutic option in particular cases 240
111In-Pentetreotide in neuroendocrine tumours: comparison between diagnostic scintigraphy and “post-therapy” whole-body scan 234
Abscesualized gliomas:predictive value of 99Tc-Leukoscan 233
Ruolo dell'imaging funzionale nel management delle emorragie cerebrali atipiche: proposta di un protocollo diagnostico derivato dalla sperimentazione clinica. 233
111In-Pentetreotide in neuroendocrine tumours. Comparison between diagnostic scintigraphy and “post-therapy” whole-body scan 230
Combined diagnosis in breast carcinoma: preoperative role of mammoscintigraphy with Tc99m-sestamibi. Our Experience 225
Ruolo della scintigrafia con HIG 99mTc (immunoglobuline policlonali marcate) nella colite ulcerosa e nel morbo di Crohn. Risultati preliminari 223
111In-Pentetreotide therapy in patients with inoperable benign intracranial tumors. 222
[68 Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177 Lu]DOTATOC PRRT: The “Theragnomics” Concept 222
2D Feature Strain Echocardiography in patients with transthyretin familial amyloid plyneuropathy and diffuse cardiac 99mTc-DPD accumulation 221
18F-FDG PET/CT Imaging of Prostate Stromal Tumor of Uncertain Malignant Potential 214
99mTc-MIBI SPECT in distinguishing neoplastic from nonneoplastic intracerebral hematoma 212
ACCIDENTAL DISCOVERY OF LUNG METATSTASES FROM DIFFERENTIATED THYROID CANCER BY TC-99M PERTECHNETATE SCAN IN A PATIENT WITH SECONDARY HYPERPARATHYROIDISM 208
A didactic experiment showing the Compton scattering by means of a clinical gamma camera 205
99mTc MIBI SPET in revealing underlying neoplasms in brain hemorrhages 201
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 201
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 201
99mTc-HM-PAO SPECT evaluation of regional cerebral blood flow modifications after paediatric hydrocephalus shunting 200
99mTc-MIBI SPECT in the differential diagnosis of brain metastases 200
2 years-survival analysis of patients with non-small cell lung cancer by means of 2deoxy-2-[18F]fluoro-D-glucose positron emission tomography: implications of maximum standardized uptake value (SUVmax) 200
Abnormal 99mTc-MIBI Uptakein left lung mimicking a neoplastic lesion in a young woman with nodular goiter. A rare pitfall of 99mTc-MIBI 200
18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor-Related "Retroperitoneal Panniculitis" 200
PRRT Retreatments: Renal Function Evaluation 199
An analytical model for improving absorbed dose calculation accuracy in non spherical autonomous functioning thyroid nodule 196
Abnormal radioiodine uptake on post-therapy whole body scan and sodium/iodine symporter expression in a dermoid cyst of the ovary: report of a case and review of the literature 195
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 195
Can neutrophil gelatinase-associated lipocalin help depict early contrast material-induced nephropathy? 195
99mTc-MIBI SPECT imaging of acute and subacute non-neoplastic brain haematomas 193
Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area 193
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 192
99mTc-Methoxy-Isobutil-Isonitrile (MIBI) scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC) 191
Association of parathyroid carcinoma and thyroid disorders: A clinical review 191
11C-Choline PET/CT based helical tomotherapy as innovative treatment approach for bone metastases in prostate cancer patients 191
Association of autonously functioning ("hot") thyroid nodules with Hashimotos' thyroiditis (HT). 190
99mTc-methoxy-isobutyl-isonitrile (MIBI) scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC) 188
ABLAZIONE RADIOMETABOLICA DEL RESIDUO TIROIDEO POST-CHIRURGICO DOPO STIMOLO CON TSH UMANO RICOMBINANTE (rhTSH) IN PAZIENTI CON OFTALMOPATIA DI GRAVES (OG) DI GRADO MODERATAMENTE SEVERO E SEVERO: STUDIO PROSPETTICO RANDOMIZZATO IN SINGOLO CIECO 187
90Y-dotatoc and/or 111In-pentetreotide in the treatment of somatostatin receptors-expressing tumors (SSTR): personal experience 186
[(186)Re]HEDP in the palliation of painful bone metastases from cancers otherthan prostate and breast. 184
153Sm-EDTMP in the treatment of painful bone metastases from prostate and breast cancer. Personal experience. 183
Accidental discovery of lung metastases from differentiated thyroid cancer by 99mTc sodium pertechnetate scan in a patient with secondary hyperparathyroidism 183
Abnormal radioiodine uptake in an abdominal dermoid cyst in a patient affected by differentiated thyroid cancer 183
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 183
BRAFV600Emutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer 183
Erratum: Mid and long-term effects on pulmonary perfusion, anatomy and diaphragamatic motility in survivors of congenital diaphragmatic hernia 182
Comparison Between 99mTc-Diphosphonate Imaging and MRI With Late Gadolinium Enhancement in Evaluating Cardiac Involvement in Patients With Transthyretin Familial Amyloid Polyneuropathy 182
18F-FACBC in prostate cancer: A systematic review and meta-analysis 182
Hyperthyroidism treatment with calculated activity of 131-Radioiodine: our experience 181
ACCUMULO DI TECNEZIO IN METASTASI POLMONARI DA CARCINOMA DIFFERENZIATO TIROIDEO (CDT): UNA RARA EVENIENZA 181
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 181
Central nervous system vasculitis after starting methimazole in a woman with Graves' disease 181
SPECT and MRI in Complex Partial Epilepsy. 180
Brunner's adenoma, esophageal reflux and gastric ulcer. A case report 180
Peptide receptor radionuclide therapy with 111IN-DTPA-Octreotide in a woman with Cabergoline-resistant giant prolactinoma 180
A methodological approach to a realistic evaluation of skin absorbed doses during manipulation of radioactive sources by means of GAMOS Monte Carlo simulations 180
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 180
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 179
Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer? 179
Diagnostic possibilities and clinical indications of policlonal labeled Ig in the bowel inflammatory disease 178
An extremely rare association of TSH-secreting pituitary adenoma, metastatic neuroendocrine tumor and Cushing’s syndrome in a patient with MEN-1 gene mutation 178
Constrictive Pericarditis: An Update on Noninvasive Multimodal Diagnosis 177
11c-choline pet/ct based helical tomotherapy as treatment approach for bone metastases in recurrent prostate cancer patients 177
186Re-HEDP in the treatment of painful bone metastases from cancers other than prostate and breast 176
Diagnosis of hepatic hemangiomas with 99mTc-labeled red blood cell scanning: value of SPECT 176
Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients 175
A Monte Carlo approach to small-scale dosimetry of solid tumour microvasculature for nuclear medicine therapies with (223)Ra-, (131)I-, (177)Lu- and (111)In-labelled radiopharmaceuticals 174
A microdosimetric model of solid tumour microvasculature for radiopharmaceuticals labeled with 223 Ra, 111 In, 131 I and 177 Lu 174
Usefulness of PET-CT scan in recurrent thyroid cancer 174
A simplified method for kidney dosimetry in Lu-177 therapies based on single SPECT-CT and multiple external probe measurements 174
Radiometabolic therapy with 131I for the ablation of the thyroid remnant in patients affected by differentiated thyroid cancer: comparison between four different activities 173
Clinico-laboratory response and haematological toxicity in patients undergoing therapy with 223RA-dichloride 173
A Monte Carlo model for the internal dosimetry of choroid plexuses in nuclear medicine procedures 173
COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings 173
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study 173
GASTROINTESTINAL SEQUELAE IN SURVIVORS OF CONGENITAL DIAPHRAGMATIC HERNIA 172
Braf V600E and 99m-TC MIBI scintigraphy are usefull diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy. 172
Safety, effectiveness and haematological toxicity of 223Radichloride: a single Centre experience 172
Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 172
ACCUMULO DI RADIOIODIO IN MIELOMENINGOCELE SECONDARIO A SPINA BIFIDA OCCULTA: PRIMA EVIDENZA DI CONDIZIONE SIMULANTE UNA METASTASI VERTEBRALE DI CARCINOMA DIFFERENZIATO DELLA TIROIDE 171
A model to evaluate S values for beta-gamma emitting radionuclides in cubic voxels 171
Can the position of malignant thyroid nodule be considered as additional risk factor for recurrent and/or metastatic disease in patients affected by low risk differentiated thyroid cancer? 171
Combined BRAFV600Eanalysis and99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation 171
Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism 170
153Sm-EDTMP in the treatment of painful bone metastases from breast cancer. 169
Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy ina real life scenario 169
Association of primary hyperparathyroidism (p-hyperPTH) with nodular toxic goiter (NTG) 168
Cardiac 99mTc-DPD uptake in subjects with Glu89Gln transthyretin gene mutation: is it the earliest sign of disease development? 168
Effectiveness, safety and haematological toxicity of 223Ra-Cl2: a single centre experience 168
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 166
Evaluation of absorbed fractions for beta-gamma radionuclides in ellipsoidal volumes of soft tissue through Geant4 165
A potentially misleading finding at somatostatin receptor scintigraphy: focal pulmonary areas of intense accumulation without computed tomography-detectable lung lesions 165
The 14CO2 urea breath test for Helicobacter pylori infection 164
Association of autonomously functioning thyroid nodules (AFTNs) with Hashimoto's thyroiditis (HT) 164
Recombinant erythropoietin and hypertension 164
Totale 23.702
Salva come PNG Salva come JPEG
Categoria #
all - tutte 214.152
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 214.152
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021371 0 0 0 0 0 0 0 0 0 0 0 371
2021/20223.461 47 468 49 110 154 34 199 177 39 521 483 1.180
2022/20239.151 745 986 441 737 699 918 131 503 3.610 61 226 94
2023/20243.491 196 332 205 284 247 655 144 232 104 418 209 465
2024/202512.709 322 295 400 853 708 480 519 2.388 2.794 828 1.241 1.881
2025/202631.013 1.752 2.007 2.485 2.000 2.439 6.718 3.624 3.837 3.816 1.385 489 461
Totale 67.451